Diagnostic value of measuring pancreatic isoamylase with a double–monoclonal antibody immunoassay in serum of hospitalized hyperamylasemic patients

1990 ◽  
Vol 4 (6) ◽  
pp. 449-452 ◽  
Author(s):  
Mauro Panteghini ◽  
Franca Pagani
Keyword(s):  
Monoclonal Antibody ◽  
Diagnostic Value ◽  
Pancreatic Isoamylase

scholarly journals BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol- resistant epitope

Blood ◽  
1989 ◽  
Vol 74 (5) ◽  
pp. 1678-1689 ◽  
Author(s):  
R Schwarting ◽  
J Gerdes ◽  
H Durkop ◽  
B Falini ◽  
S Pileri ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Plasma Cells ◽  
Large Cell ◽  
Diagnostic Value ◽  
Paraffin Sections ◽  
Lymphomatoid Papulosis ◽  
Tissue Sections ◽  
Hodgkin's Lymphomas ◽  
Cd30 Antigen

Abstract The production and characterization of a monoclonal antibody (MoAb) designated Ber-H2, directed against a new epitope of the Ki-1 (CD30) antigen, are described. In comparison with the formerly reported Ki-1 MoAb whose reactivity with Hodgkin and Reed-Sternberg (H-RS) cells in frozen tissue sections is well-documented, the Ber-H2 MoAb showed new, important features: the labeling intensity of the Ber-H2 MoAb was much stronger, and the number of positively labeled cells was higher. Most important, however, was that the Ber-H2 MoAb could be applied in routinely processed, formaldehyde-fixed, paraffin-embedded tissue sections. Therefore, it was possible to investigate an unprecedented number of tumors received as frozen or formaldehyde-fixed material for expression of the CD30 antigen. Beside Hodgkin's disease, the Ber-H2 MoAb labeled a variable number of cells in lymphomatoid papulosis, peripheral T-cell lymphomas, and angoimmunoblastic lymphadenopathy. Among B-cell non-Hodgkin's lymphomas (NHLs), some cases containing large centroblast-like or immunoblast-like cells or displaying plasma- cellular differentiation were positive. This finding was in keeping with the reactivity of the Ber-H2 MoAb with activated B-cell blasts and a subpopulation of plasma cells in paraffin sections of normal lymphoid tissue. The diagnostic value of the Ber-H2 MoAb was most significant for a group of anaplastic large-cell (ALC) lymphomas (formerly frequently referred to as malignant histiocytosis or regressive atypical histiocytosis), of which more than 50 cases could be investigated, owing to applicability in paraffin sections. Although about one third of these ALC lymphomas did not express the leukocyte common (CD45) antigen, they were consistently reactive with the Ber-H2 MoAb in both frozen and paraffin-embedded tissue sections. Using the Ber-H2 MoAb, these Ki-1 lymphomas could be easily distinguished from other nonlymphoid anaplastic large-cell tumors.

Development of an enzyme-linked immunosorbent assay with a monoclonal antibody prepared against alpha 1-antitrypsin for diagnostic screening of inflammatory disorders

1990 ◽  
Vol 36 (2) ◽  
pp. 277-282 ◽  
Author(s):  
B Silvestrini ◽  
A Guglielmotti ◽  
L Saso ◽  
C Milanese ◽  
E Melanitou ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Immunosorbent Assay ◽  
Lupus Erythematosus ◽  
Diagnostic Value ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Samples ◽  
Diagnostic Screening ◽  
Inflammatory Disorders ◽  
Specific Epitope ◽  
Alpha 1 Antitrypsin

Abstract A monoclonal antibody, designated A2a18b8, of IgG1 class prepared against human alpha 1-antitrypsin, cross-reacts with alpha 1-antitrypsin in the serum of rat and baboon, but not with alpha 1-antitrypsin in serum of rabbit, pig, hamster, guinea pig, dog, or turtle. We used A2a18b8 in an enzyme-linked immunosorbent assay (ELISA) developed for human alpha 1-antitrypsin. Preliminary ELISA screening of 247 serum samples from patients with various inflammatory disorders indicated that the concentration of a specific epitope(s) on alpha 1-antitrypsin recognized by this monoclonal antibody was increased significantly in patients with active systemic lupus erythematosus, mixed connective tissue disease, and rheumatoid arthritis, but not in patients with sclerodermic disorders or Sjögren's syndrome. Evidently, A2a18b8 has diagnostic value in that it selectively recognizes a specific epitope(s) on alpha 1-antitrypsin that is (are) apparently exposed during selective inflammatory disorders.

scholarly journals Fibronectin fragments in human seminal plasma.

2005 ◽  
Vol 52 (2) ◽  
pp. 557-560 ◽  
Author(s):  
Iwona Katnik-Prastowska ◽  
Magdalena Przybysz ◽  
Anna Chełmońska-Soyta
Keyword(s):  
Monoclonal Antibody ◽  
Seminal Plasma ◽  
Diagnostic Value ◽  
Plasma Samples ◽  
Human Seminal Plasma ◽  
Terminal Domain ◽  
Fibronectin Fragments ◽  
Semen Characteristics

The study has revealed the presence of fibronectin (FN) fragments and a lack of intact FN in 72 seminal plasma samples. The FN fragmentation was examined by immunoblotting with a monoclonal antibody specific to the central cellular FN domain and was confirmed with a monoclonal antibody directed to the C-terminal domain of FN. Nine FN fragments between 60 and 200 kDa and five fragments of 60-150 kDa were identified in seminal plasma samples of normozoospermic and of terato-, oligoterato-, and oligoasthenoterato-spermic groups, respectively. The relative amounts of the 60, 90 and 100 kDa FN fragments were 2-3 times higher in seminal plasmas with abnormal semen characteristics than in the normozoospermic group. The results suggest that seminal plasma FN fragments may contribute to fertilization and the analysis of FN fragmentation may have a diagnostic value in andrological investigations.

scholarly journals Comparison of the diagnostic value of serum pancreatic isoamylase and immunoreactive trypsin measurement in patients with cystic fibrosis.

1982 ◽  
Vol 35 (5) ◽  
pp. 547-549 ◽  
Author(s):  
R C Brown ◽  
D M Chalmers ◽  
V L Rowe ◽  
J Kelleher ◽  
J M Littlewood ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Diagnostic Value ◽  
Immunoreactive Trypsin ◽  
Pancreatic Isoamylase

Multicenter evaluation of a specific pancreatic isoamylase assay based on a double monoclonal-antibody technique.

1988 ◽  
Vol 34 (10) ◽  
pp. 2096-2102 ◽  
Author(s):  
N W Tietz ◽  
A Burlina ◽  
W Gerhardt ◽  
W Junge ◽  
P Malfertheiner ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Wheat Germ ◽  
Reference Intervals ◽  
Antibody Technique ◽  
Clinical Sensitivity ◽  
Activity Concentrations ◽  
Interlaboratory Studies ◽  
Inhibitor Method ◽  
Pancreatic Isoamylase ◽  
High Concentrations

Abstract Eleven evaluators from nine laboratories in five countries evaluated a new immunoinhibition method for pancreatic isoamylase determination that is as simple to perform as that for total amylase. The precision at low and intermediate activity concentrations was superior, and at high concentrations it equalled that of the wheat-germ inhibitor method. The test was linear to approximately 2000 U/L, depending on the instrumentation used. The percentage salivary isoamylase activities remaining in specimens after reaction with two monoclonal antibodies ranged from 2 to 4.4%. Comparative studies showed good correlation with the wheat-germ inhibitor (r greater than 0.978) and electrophoresis methods (r = 0.920). Hemolysis, lipemia, and bilirubinemia have no effect on results. Interlaboratory studies demonstrated excellent transferability of the method, if instruments are calibrated with the same calibrator. Reference intervals for pancreatic isoamylase are 13 to 64 U/L (25 degrees C), 13 to 83 U/L (30 degrees C), and 17 to 115 U/L (37 degrees C). A clinical evaluation of patients with acute pancreatitis showed that pancreatic isoamylase has a greater clinical sensitivity than total amylase.

BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol- resistant epitope

Blood ◽  
1989 ◽  
Vol 74 (5) ◽  
pp. 1678-1689 ◽  
Author(s):  
R Schwarting ◽  
J Gerdes ◽  
H Durkop ◽  
B Falini ◽  
S Pileri ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
B Cell ◽  
Plasma Cells ◽  
Large Cell ◽  
Diagnostic Value ◽  
Paraffin Sections ◽  
Lymphomatoid Papulosis ◽  
Tissue Sections ◽  
Hodgkin's Lymphomas ◽  
Cd30 Antigen

The production and characterization of a monoclonal antibody (MoAb) designated Ber-H2, directed against a new epitope of the Ki-1 (CD30) antigen, are described. In comparison with the formerly reported Ki-1 MoAb whose reactivity with Hodgkin and Reed-Sternberg (H-RS) cells in frozen tissue sections is well-documented, the Ber-H2 MoAb showed new, important features: the labeling intensity of the Ber-H2 MoAb was much stronger, and the number of positively labeled cells was higher. Most important, however, was that the Ber-H2 MoAb could be applied in routinely processed, formaldehyde-fixed, paraffin-embedded tissue sections. Therefore, it was possible to investigate an unprecedented number of tumors received as frozen or formaldehyde-fixed material for expression of the CD30 antigen. Beside Hodgkin's disease, the Ber-H2 MoAb labeled a variable number of cells in lymphomatoid papulosis, peripheral T-cell lymphomas, and angoimmunoblastic lymphadenopathy. Among B-cell non-Hodgkin's lymphomas (NHLs), some cases containing large centroblast-like or immunoblast-like cells or displaying plasma- cellular differentiation were positive. This finding was in keeping with the reactivity of the Ber-H2 MoAb with activated B-cell blasts and a subpopulation of plasma cells in paraffin sections of normal lymphoid tissue. The diagnostic value of the Ber-H2 MoAb was most significant for a group of anaplastic large-cell (ALC) lymphomas (formerly frequently referred to as malignant histiocytosis or regressive atypical histiocytosis), of which more than 50 cases could be investigated, owing to applicability in paraffin sections. Although about one third of these ALC lymphomas did not express the leukocyte common (CD45) antigen, they were consistently reactive with the Ber-H2 MoAb in both frozen and paraffin-embedded tissue sections. Using the Ber-H2 MoAb, these Ki-1 lymphomas could be easily distinguished from other nonlymphoid anaplastic large-cell tumors.

Sign in / Sign up

Export Citation Format

Share Document